CNS Pharmaceuticals shares surge 27.43% after-hours as three abstracts accepted for SNO 2025 meeting presentations.

CNS Pharmaceuticals (NASDAQ:CNSP) surged 27.43% in after-hours trading following the announcement that three abstracts detailing its drug candidates’ clinical data were accepted for poster presentation at the Society for Neuro-Oncology (SNO) 30th Annual Meeting. The presentations include preliminary results of Berubicin’s activity against pediatric diffuse midline glioma, a planned Phase 2 trial of TPI 287 combined with Bevacizumab for glioblastoma, and primary trial results comparing Berubicin to Lomustine in glioblastoma patients. These updates highlight therapeutic potential and clinical progress in CNS-targeted cancers, likely driving investor optimism about the company’s pipeline.